Citations

Mayo Clinic

Showing 10 of 108551 citations.

Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromes
Zarif, Talal El , Khalid, Ahmed Bilal, Rahme, Serena, Zhong, Caiwei , Salame, Marita , Freeman, Dory , El‐Am, Edward , Ravishankar, Arjun , Ahmad, Bachar , Nana, Frank Aboubakar , Kaldas, David , Naqash, Abdul Rafeh , LeBoeuf, Nicole R. , Malgeri, Andrea , Gupta, Shruti , Al‐Hader, Ahmad, Sparks, Jeffrey A. , Linnoila, Jenny, McKay, Rana R. , Dilling, Thomas J. , Adib, Elio , Najem, Elie, Kim, So Yeon , Sonpavde, Guru , El Zarif, Talal , Gupta, Shruti , Marron, Thomas , Choueiri, Toni K , Adib, Elio , Kim, So Yeon , Sonpavde, Guru , Sparks, Jeffrey A , Aboubakar Nana, Frank , Naqash, Abdul Rafeh , Nassar, Amin H. , Kwak, Lucia , Farhat, Elias Bou , Sharon, Elad , Cortellini, Alessio , Hamnvik, Ole‐Petter R. , Mouhieddine, Tarek H. , Parikh, Kaushal , Choueiri, Toni K.

Journal for ImmunoTherapy of Cancer | March 5, 2024 | Volume: 12 | Issue: 3 | Pages: e008724

10.1136/jitc-2023-008724 | PMID 38448038 Get It

Background Patients with paraneoplastic syndromes (PNS) are excluded from clinical trials involving immune checkpoint inhibitors (ICIs) due to safety concerns. Moreover, real-world data on efficacy and safety is scarce. Methods In this retrospective study, data were collected on patients with PNS and solid tumors receiving ICI between 2015 and 2022 at nine institutions. Patients were classified into: Cohort 1 (pre-existing PNS before ICI initiation), cohort 2 (PNS during ICI treatment), and cohort 3 (PNS after ICI discontinuation). Patients with metastatic non-small cell lung cancer (NSCLC) (mNSCLC) from cohort 1 were matched to patients who were PNS-free at each institution up to a 1:3 ratio for age, sex, type of ICI, use of concurrent chemotherapy, and number of lines of systemic therapy prior to ICI initiation. Kaplan-Meier method was used to assess overall survival (OS) and time-to-next treatment (TTNT). Results Among 109 patients with PNS treated with ICIs, median age at ICI initiation was 67 years (IQR: 58–74). The most represented cancer type was NSCLC (n=39, 36%). In cohort 1 (n=55), PNS exacerbations occurred in 16 (29%) patients with median time to exacerbation after ICI of 1.1 months (IQR: 0.7–3.3). Exacerbation or de novo PNS prompted temporary/permanent interruption of ICIs in 14 (13%) patients. For cohort 2 (n=16), median time between ICI initiation and de novo PNS was 1.2 months (IQR: 0.4–3.5). Treatment-related adverse events (trAEs) occurred in 43 (39%) patients. Grade ≥3 trAEs occurred in 18 (17%) patients. PNS-directed immunosuppressive therapy was required in 55 (50%) patients. We matched 18 patients with mNSCLC and PNS (cohort 1) to 40 without PNS, treated with ICIs. There was no significant difference in OS or TTNT between patients with mNSCLC with and without PNS, although a trend was seen towards worse outcomes in patients with PNS. TrAEs occurred in 6/18 (33%) and 14/40 (35%), respectively. Grade ≥3 trAEs occurred in 4 (22%) patients with PNS and 7 (18%) patients without PNS. Conclusions Exacerbations of pre-existing PNS occurred in 29% of patients treated with ICIs and both exacerbations and de novo PNS occur early in the ICI course. TrAE from ICIs were similar between patients with and without PNS. Our data suggest that pre-existing PNS should not preclude consideration of ICI therapy although patients may not derive the same clinical benefit compared with patients without PNS.
Atypical Bilateral Idiopathic Inflammatory Cavernous Sinus Syndrome Responsive to Cyclophosphamide
Nathoo, Nabeela , Chodnicki, Kevin D. , Krecke, Karl N. , Nguyen, Aivi T. , Toledano, Michel , Kantarci, Orhun H. , Nguyen, Aivi T , Nathoo, Nabeela , Gompel, Jamie J. Van

Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques | March 5, 2024 | Volume: 52 | Issue: 1 | Pages: 159-161

10.1017/cjn.2024.29 | PMID 38443750 Get It

Patient-Derived Tumor Xenograft Study with CDK4/6 Inhibitor Plus AKT Inhibitor for the Management of Metastatic Castration-Resistant Prostate Cancer
Kase, Adam M. , Trynda, Justyna , Miller, James L. , Miller, Erin , Petit, Joachim L. , Barrett, Michael T. , Zhou, Yumei , Parent, Ephraim E. , Cai, Hancheng , Knight, Joshua A. , Orme, Jacob J. , Durham, William F., Metz, Thomas , Meurice, Nathalie , Edenfield, Brandy , Demirer, Aylin Alasonyalılar , Hickman, Peyton G. , Pawlush, Matthew L. , Wickland, Daniel P. , Tan, Winston , Copland, John A. , Gleba, Justyna , Petit, Joachim L , Orme, Jacob J , Reynolds, Jordan P , Durham, William F , Metz, Thomas M , Meurice, Nathalie , Edenfield, Brandy , Alasonyalilar Demirer, Aylin , Bilgili, Ahmet , Hickman, Peyton G , Pawlush, Matthew L , Marlow, Laura , Wickland, Daniel P , Tan, Winston , Copland, John A , Knight, Joshua A , Parent, Ephraim E , Cai, Hancheng , Reynolds, Jordan , Bilgili, Ahmet , Marlow, Laura A.

Molecular Cancer Therapeutics | March 5, 2024 | Volume: 23 | Issue: 6 | Pages: 823-835

10.1158/1535-7163.mct-23-0296 | PMID 38442920 Get It

Abstract Metastatic castration-resistant prostate cancer (mCRPC) is an aggressive malignancy with poor outcomes. To investigate novel therapeutic strategies, we characterized three new metastatic prostate cancer patient derived-tumor xenograft (PDTX) models and developed 3D spheroids from each to investigate molecular targeted therapy combinations including CDK4/6 inhibitors (CDK4/6i) with AKT inhibitors (ATKi). Metastatic prostate cancer tissue was collected and three PDTX models were established and characterized using whole-exome sequencing. PDTX 3D spheroids were developed from these three PDTXs to show resistance patterns and test novel molecular-targeted therapies. CDK4/6i's were combined with AKTi's to assess synergistic antitumor response to prove our hypothesis that blockade of AKT overcomes drug resistance to CDK4/6i. This combination was evaluated in PDTX three-dimensional (3D) spheroids and in vivo experiments with responses measured by tumor volumes, PSA, and Ga-68 PSMA-11 PET-CT imaging. We demonstrated CDK4/6i's with AKTi's possess synergistic antitumor activity in three mCRPC PDTX models. These models have multiple unique pathogenic and deleterious genomic alterations with resistance to single-agent CDK4/6i's. Despite this, combination therapy with AKTi's was able to overcome resistance mechanisms. The IHC and Western blot analysis confirmed on target effects, whereas tumor volume, serum PSA ELISA, and radionuclide imaging demonstrated response to therapy with statistically significant SUV differences seen with Ga-68 PSMA-11 PET-CT. These preclinical data demonstrating antitumor synergy by overcoming single-agent CDK 4/6i as well as AKTi drug resistance provide the rational for a clinical trial combining a CDK4/6i with an AKTi in patients with mCRPC whose tumor expresses wild-type retinoblastoma 1.
Carotid Artery Disease: Then and Now
Brott, Thomas G. , Roubin, Gary S. , Moore, Wesley S. , Meschia, James F. , Meschia, James F

Stroke: Vascular and Interventional Neurology | March 5, 2024 | Volume: 4 | Issue: 2 | Pages: No page available

10.1161/svin.123.001076 | PMID 42100551 Get It

Nosocomial Infections in Adults Receiving Extracorporeal Membrane Oxygenation: A Review for Infectious Diseases Clinicians
Marcus, Joseph E , Shah, Aditya , Peek, Giles J. , MacLaren, Graeme , Marcus, Joseph

Clinical Infectious Diseases | March 5, 2024 | Volume: 79 | Issue: 2 | Pages: 412-419

10.1093/cid/ciae120 | PMID 38442737 Get It

Abstract Over the past 10 years, there has been a rapid expansion in the use of extracorporeal membrane oxygenation (ECMO) in the care of patients with refractory cardiac or respiratory failure. Infectious diseases clinicians must reconcile conflicting evidence from limited studies as they develop practices at their own institutions, which has resulted in considerably different practices globally. This review describes infection control and prevention as well as antimicrobial prophylaxis strategies in this population. Data on diagnostics and treatment for patients receiving ECMO with a focus on diagnostic and antimicrobial stewardship is then examined. This review summarizes gaps in the current ECMO literature and proposes future needs, including developing clear definitions for infections and encouraging transparent reporting of practices at individual facilities in future clinical trials.
Characteristics of systemic testosterone therapy for female hypoactive sexual desire disorder—a claims database analysis
Agrawal, Pranjal , Lee, Yeonsoo Sara , Dumas, Kathryn, Kohn, Jaden R. , Yee, Alyssa M, Clifton, Marisa , Sara Lee, Yeonsoo , Grutman, Aurora J. , Kohn, Taylor P.

The Journal of Sexual Medicine | March 5, 2024 | Volume: 21 | Issue: 4 | Pages: 288-293

10.1093/jsxmed/qdae013 | PMID 38441520 Get It

Abstract Background Testosterone therapy (TTh) is recommended for postmenopausal women with hypoactive sexual desire disorder (HSDD); however, there remain insufficient data to support use of TTh in premenopausal women with sexual dysfunction. Aim In this study, we used a large national database to evaluate prescribing trends of TTh for women with HSDD. Methods We conducted a cohort analysis of information from electronic health records acquired from the data network TriNetX Diamond. The study cohort consisted of women 18-70 years of age with a diagnosis of HSDD. We analyzed trends of testosterone prescriptions, routes of testosterone administration, and coadministration of testosterone with estrogen. Outcomes Despite an increase in rates of testosterone prescriptions for HSDD, there remains a high degree of variability in the duration of treatment, route of administration, and coadministration of estrogen with significant underprescription of testosterone. Results Our query of the TriNetX database led to the identification of 33 418 women diagnosed with HSDD at a mean age of 44.2 ± 10.8 years, among whom 850 (2.54%) women received a testosterone prescription. The testosterone prescriptions were highly variable with regard to duration and route of administration and coadministration with estrogen. For all patients until 2015, the prevalence of testosterone prescriptions for HSDD showed a positive quadratic relation was observed. Since 2015 a linear increase in prevalence was observed, with the highest rate of increase for patients aged 41-55 years. Clinical Implications The findings of this study reveal a significant need for further research investigating the optimal use of TTh to enhance the sexual health of women with HSDD, and further studies on the long-term effects of testosterone use must be undertaken to ensure that patients have access to safe and effective treatment. Strengths and Limitations Limitations to this study include patient de-identification and lack of availability of testosterone dosage data. However, this study also has many strengths, including being the first, to our knowledge, to characterize the prescribing trends of testosterone for women with HSDD. Conclusion Testosterone therapy should be considered as a potential therapy for premenopausal female patients with HSDD. Further studies on the long-term effects of testosterone use must be undertaken to address disparities in the management of HSDD and to ensure patients can access treatment.
Medical Student Intent to Practice in Underserved Areas—Reply
Dyrbye, Liselotte N. , West, Colin P.

JAMA | March 5, 2024 | Volume: 331 | Issue: 9 | Pages: 802

10.1001/jama.2023.28306 | PMID 38441585 Get It

Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma
Ghobrial, Irene M. , Kumar, Shaji , Mateos, María‐Victoria , Bergsagel, P. Leif , Chesi, Marta , Dhodapkar, Madhav V. , Getz, Gad , Manier, Salomon , Nuvolone, Mario , O’Donnell, Elizabeth , Sklavenitis‐Pistofidis, Romanos , Sperling, Adam S. , Vassiliou, George S. , Munshi, Nikhil C. , Bergsagel, P. Leif , Gormley, Nicole , Kumar, Shaji K , Mateos, María-Victoria , Chesi, Marta , Dhodapkar, Madhav V , Getz, Gad , Kastritis, Efstathios , Kristinsson, Sigurdur Y , Martinez-Climent, Jose Angel , Manier, Salomon , Marinac, Catherine R , Maura, Francesco , Morgan, Gareth J , Davies, Faith E , Nadeem, Omar , Nuvolone, Mario , Paiva, Bruno , O'Donnell, Elizabeth , Prosper, Felipe , Shah, Urvi A , Sklavenitis-Pistofidis, Romanos , Sperling, Adam S , Munshi, Nikhil C , Castle, Philip E , Anderson, Kenneth C , San-Miguel, Jesus , Ghobrial, Irene M , Gormley, Nicole , Dispenzieri, Angela , Fonseca, Rafaël , Kastritis, Efstathios , Martinez‐Climent, José A. , Marinac, Catherine R. , Maura, Francesco , Morgan, Gareth J. , Davies, Faith E. , Nadeem, Omar , Paiva, Bruno , Prósper, Felipe , Shah, Urvi A. , Anderson, Kenneth C. , Miguel, Jesús F. San

Blood Cancer Discovery | March 5, 2024 | Volume: 5 | Issue: 3 | Pages: 146-152

10.1158/2643-3230.bcd-24-0022 | PMID 38441243 Get It

Summary: While the current approach to precursor hematologic conditions is to “watch and wait,” this may change with the development of therapies that are safe and extend survival or delay the onset of symptomatic disease. The goal of future therapies in precursor hematologic conditions is to improve survival and prevent or delay the development of symptomatic disease while maximizing safety. Clinical trial considerations in this field include identifying an appropriate at-risk population, safety assessments, dose selection, primary and secondary trial endpoints including surrogate endpoints, control arms, and quality-of-life metrics, all of which may enable more precise benefit–risk assessment.
Reply to Kidd et al., “Inconsistencies within the proposed framework for stabilizing fungal nomenclature risk further confusion”
Walsh, Thomas J. , Ahmed, Sarah , Alastruey‐Izquierdo, Ana , Alexander, Barbara D. , Arendrup, Maiken Cavling , Babady, Esther , Balada-Llasat, Joan-Miquel, Borman, Andrew M. , Colgrove, Robert C. , Cornely, Oliver A. , Fuller, Jeff, Gibas, Connie Fe C., Glasgow, Heather, Groll, Andreas H. , Haase, Gerhard , Hanson, Kimberly E. , Harrington, Amanda, Hayden, Randall T. , Hubka, Vít , Johnson, Kristie, Li, Ruoyu , Lanternier, Fanny , Lee, Francesca , Luethy, Paul M. , Kwon‐Chung, Kyung J., Palavecino, Elizabeth , Pancholi, Preeti , Pappas, Peter G. , Procop, Gary W. , Rhoads, Daniel D. , Riedel, Stefan , Stevens, Bryan S. , Sullivan, Kaede Ota, Vergidis, Paschalis , Roilides, Emmanuel , Seyedmousavi, Amir, Tao, Lili , Vicente, Vânia Aparecida , Vitale, Roxana G. , Wengenack, Nancy L. , Westblade, Lars F. , White, Lewis, Wojewoda, Christina , Babady, N. Esther , Seyedmousavi, Seyedmojtaba , de Hoog, Sybren , Walsh, Thomas J , Alastruey-Izquierdo, A , Arendrup, Maiken Cavling , Borman, Andrew , Groll, Andreas H , Hanson, Kimberly , Hayden, Randall T , Hoenigl, Martin , Kus, Julianne V , Meis, Jacques F , Leal, Sixto M , Lockhart, Shawn R. , Kwon-Chung, Kyung J , Nguyen, M Hong , Palavecino, Elizabeth , Pancholi, Preeti , Rhoads, Daniel D , Riedel, Stefan , Vergidis, Paschalis , Roilides, Emmanuel , Wengenack, Nancy L , Wiederhold, Nathan , White, Lewis , Wojewoda, Christina M , Zhang, Sean X , Cornely, Oliver A , Ahmed, Sarah A , Luethy, Paul , Bai, Feng‐Yan , Chowdhary, Anuradha , Clark, Andrew, Dingle, Tanis C. , Dufresne, Philippe J. , Gangneux, Jean‐Pierre , Gräser, Yvonne , Guillot, Jacques , Hawksworth, David L. , Hoenigl, Martin , Kus, Julianne V. , Lackner, Michaela , Leal, Sixto M. , Martin, Isabella W. , Meyer, Wieland , Ostrosky‐Zeichner, Luis , Redhead, Scott A. , Stevens, Bryan, Wang, Qiming , Wiederhold, Nathan P. , Zhang, Sean X.

Journal of Clinical Microbiology | March 5, 2024 | Volume: 62 | Issue: 4 | Pages: No page available

10.1128/jcm.01625-23 | PMID 38441056 Get It

A Century of Colon and Rectal Surgery at Mayo Clinic (1924–2024): Honoring Our Founder Louis A. Buie Sr., M.D., D.Sc.
Kelley, Scott R. , Dozois, Eric J. , Kelley, Scott R

Diseases of the Colon & Rectum | March 5, 2024 | Volume: 67 | Issue: 6 | Pages: 755-761

10.1097/dcr.0000000000003314 | PMID 38441192 Get It